Position in ZYME
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$8,048,532
+$2,143,556 QoQ
Shares Held
321,427
+43.3% QoQ
Ownership
0.440%
of shares outstanding
% of Portfolio
0.27%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ZYME Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026SummitTX Capital, L.P. holds $204,820,246 across 62 Biotechnology names. ZYME ranks #10 (3.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TERN |
Terns Pharmaceuticals, Inc.
|
312,181 | $16,458,182 | |
| 2 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
165,599 | $14,402,145 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
73,222 | $13,842,619 | |
| 4 | PRAX |
Praxis Precision Medicines, Inc.
|
36,838 | $11,868,835 | |
| 5 | COGT |
Cogent Biosciences, Inc.
|
293,780 | $11,307,592 | |
| 6 | PHAT |
Phathom Pharmaceuticals, Inc.
|
995,885 | $11,064,282 | |
| 7 | INBX |
Inhibrx Biosciences, Inc.
|
137,821 | $9,265,705 | |
| 8 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
100,044 | $8,395,692 |
All Filings in ZYME
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $8,048,532 | 321,427 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $5,904,976 | 224,268 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||